CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on th... CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. Show more
A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of start-up preparations - full enrollment...
CEL-SCI Corporation (βCEL-SCIβ or the βCompanyβ) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,130,000...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0257 | 6.92162671694 | 0.3713 | 0.434 | 0.3633 | 641711 | 0.41595143 | CS |
4 | -0.283 | -41.6176470588 | 0.68 | 0.82 | 0.3567 | 1755787 | 0.4362934 | CS |
12 | -0.533 | -57.311827957 | 0.93 | 1.09 | 0.3567 | 1032809 | 0.55712739 | CS |
26 | -1.073 | -72.9931972789 | 1.47 | 2.2199 | 0.3567 | 1128179 | 0.97220467 | CS |
52 | -2.053 | -83.7959183673 | 2.45 | 3.08 | 0.3567 | 727163 | 1.14665292 | CS |
156 | -6.013 | -93.8065522621 | 6.41 | 6.55 | 0.3567 | 660220 | 2.40437383 | CS |
260 | -9.203 | -95.8645833333 | 9.6 | 40.91 | 0.3567 | 779607 | 8.16066963 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.